Ethical questions concerning newborn genetic screening

Area of Science:

• Public Health
• Genetics
• Bioethics

Background:

• Newborn screening is a vital public health initiative to detect diseases early in infants, enabling timely intervention before symptoms manifest.
• The inclusion of diseases in screening programs involves medical, public health, and economic factors, requiring well-understood disease natural history and effective early treatments.
• Current screening relies on biochemical markers, but advancements in technology now enable genetic screening, introducing new possibilities and challenges.

Purpose of the Study:

• To evaluate the criteria for including diseases in newborn screening programs.
• To explore the implications of new genetic screening technologies in the context of newborn screening.
• To identify and discuss the ethical challenges associated with neonatal screening.

Main Methods:

• Literature review and analysis of established criteria for newborn screening.
• Examination of the technical feasibility and public health impact of genetic screening in newborns.
• Identification and discussion of key ethical concerns related to neonatal screening.

Main Results:

• Established criteria for newborn screening include disease significance, known natural history, test availability, effective early treatment, and robust healthcare systems.
• Genetic screening offers new potential but also presents technical hurdles.
• Six major ethical concerns were identified: illness type, overdiagnosis/overtreatment, informed consent, data confidentiality, and justice/legal regulation.

Conclusions:

• Newborn screening decisions require a multidisciplinary approach, balancing public health needs with economic considerations.
• The advent of genetic screening necessitates careful consideration of its ethical dimensions.
• Addressing the identified ethical issues is crucial for the responsible implementation of advanced neonatal screening programs.